Nuvalent teams up with Guardant Health for companion diagnostics

Massachusetts biotech Nuvalent is turning to Guardant Health to develop companion diagnostics for its targeted cancer drugs, signing a multi-year deal to tap into Guardant’s “Infinity” platform.&nb | Massachusetts biotech Nuvalent is turning to Guardant Health to develop companion diagnostics for its targeted cancer drugs, signing a multi-year deal to tap into Guardant’s “Infinity” platform. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry…

Source: FierceBiotech